GlassScriptPhysician profile
Priyanka Patel
NPI 1912469834
$3,625.70
in general payments reported to CMS, 2019-2025
22 companies · $531 in 2025
The $531 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $259 · 2023: $582 · 2024: $2,036 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962 · Education: $171 · Travel and Lodging: $16.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.81 |
| Education | $171.00 |
| Travel and Lodging | $16.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $494.59 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Abbvie INC. | $426.85 | 2023-2025 | |
| Genzyme Corporation | $400.85 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $320.22 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $275.94 | 2023-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $236.93 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $235.97 | 2023-2024 | Ilumya |
| Ucb, INC. | $219.46 | 2023-2024 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $144.98 | 2021-2022 | |
| Stemline Therapeutics INC. | $122.11 | 2023 | Orserdu |
| Incyte Corporation | $114.53 | 2023-2024 | Opzelura |
| Janssen Biotech, INC. | $99.00 | 2024 | Tremfya |
| Pfizer INC. | $97.61 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.54 | 2023-2024 | Jublia, Cabtreo, Arazlo |
| E.R. Squibb & Sons, L.L.C. | $90.61 | 2024 | Sotyktu |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58.23 | 2023-2024 | Otezla |
| Fresenius Kabi USA, LLC | $51.41 | 2023 | Idacio |
| Almirall LLC | $42.35 | 2024 | Klisyri |
| Dermavant Sciences, INC. | $35.57 | 2023 | Vtama |
| Mayne Pharma Commercial LLC | $26.95 | 2023 | |
| Avanos Medical | $18.36 | 2025 | On-Q Pump and Accessories |
| Arcutis Biotherapeutics, INC. | $15.64 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priyanka Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.